According to diabetes news today, Amylin Pharmaceuticals Inc revealed that they had received a request from the Food and Drug Administration for information about manufacturing and a risk mitigation plan for their proposed once a week diabetes treatment .
Amylin have partnered with Eli Lilly and Company as well as Alkermes Inc. The FDA has requested a focus on product labelling for the new diabetes drug Bydureon (trade name for exenatide.) The FDA also require risk mitigation data and manufacturing information, which Amylin will now work to supply.
Exenatide is a once-per-week version of injectable diabetes treatment Byetta, currently being taken twice per day by thousands of diabetes patients in the UK. The drug will be one of the first in the GLP-1 class, to accompany the Novo Nordisk drug Victoza .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…